Boston Scientific stock heads toward an October 28 outlook reset in 2026

Published on 10/06/2026 at 17:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Boston Scientific stock heads toward an October 28 outlook update after a cyberattack disrupted operations. Q2 revenue rose 7.5 percent to USD 5.442 billion.

NYSE-Handelsparkett mit großen Bildschirmen, die REIT-Index und Immobilien-Sektorcharts zeigen — Boston Properties US1011371077 erscheint auf Bildschirmen des NYSE Handelsparkett mit Immobilien REIT Sektor Kursdiagrammen, Illustration mit AI erstellt.

Boston Scientific stock was trading at USD 42.55 on the NYSE on October 6, 2026, up 0.35 percent at 11:39 a.m. ET, while the company heads toward an October 28 outlook update. The cybersecurity incident disrupted manufacturing and customer shipments, and Reuters reported on September 8, 2026, that Boston Scientific no longer expected to meet its earlier third-quarter and full-year 2026 forecasts.

Cyberattack changes the outlook

Boston Scientific identified unauthorized activity in its information technology systems on August 25, 2026. The disruption affected manufacturing, order processing and shipments, although distribution centers, sterilization operations and most manufacturing facilities had resumed activity by the September 8, 2026 report.

According to StockTitan, Boston Scientific expects to update its 2026 outlook on October 28, 2026 and expects the incident to affect third-quarter and full-year results. That date gives investors the next measurable checkpoint for shipment recovery, revenue recapture and the companys 2027 growth framework.

Quarterly growth meets tougher backdrop

Boston Scientific reported USD 5.442 billion in Q2 2026 revenue, up 7.5 percent from Q2 2025, while adjusted EPS reached USD 0.86 versus a USD 0.83 consensus estimate, according to StockTitan. The finance data for the same quarter shows total revenue of USD 5.442 billion and operating profit of USD 1.178 billion.

Before the cyberattack, the company had guided for Q3 2026 adjusted EPS of USD 0.80 to USD 0.82 and full-year adjusted EPS of USD 3.28 to USD 3.32. The gap between the Q2 adjusted EPS result and consensus was USD 0.03, but the October update now matters more than the earlier beat because it will quantify the operational interruption.

Analysts still see valuation upside

Citigroup lowered its Boston Scientific price target from USD 50 to USD 48 on October 5, 2026, while maintaining a neutral rating, according to MarketBeat. The same report lists 23 Buy, five Hold and two Sell ratings, producing a Moderate Buy consensus and an average price target of USD 67.88, which lies 59.5 percent above the October 6 price.

Stock remains near yearly low

At USD 42.55 on October 6, 2026, Boston Scientific stock stood 59.7 percent below its 52-week high of USD 105.65 and USD 0.61 above its 52-week low of USD 41.94. Market capitalization was USD 63.2 billion and trading volume was 3,230,911 shares at the same time.